Valuation: Orgenesis Inc.

Market Cap 985K 880K 819K 745K 1.41M 95.35M 1.41M 9.85M 3.86M 48.61M 3.7M 3.62M 156M P/E 2023
-0.26x
P/E 2024 -0.17x
Enterprise Value 19.17M 17.12M 15.92M 14.48M 27.35M 1.85B 27.47M 192M 75.09M 946M 71.97M 70.4M 3.03B EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
1 day+181.25%
1 week-18.18%
Current month-18.18%
1 month+9.12%
3 months+12.50%
6 months+181.25%
Current year+200.00%
1 week 0.35
Extreme 0.35
0.55
1 month 0.03
Extreme 0.0327
0.67
Current year 0
Extreme 0.001
0.84
1 year 0
Extreme 0.001
1
3 years 0
Extreme 0.0001
10.8
5 years 0
Extreme 0.0001
52
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 2012-02-01
Chief Executive Officer 57 2013-12-23
Director of Finance/CFO 51 2026-03-09
Director TitleAgeSince
Chairman 57 2014-08-13
Director/Board Member 64 2024-07-07
Director/Board Member 47 2024-10-27
Date Insider Type Main position Quantity % Market Cap. Importance
3/5/25 Other 1,200,000 23.2142%
12/12/24 Free

Director

1,500 0.0290%
12/12/24 Free

Director

1,835 0.0355%
Change 5-day change 1-year change 3-year change Capi.($)
+181.25%-18.18%-4.26%-95.31% 3.43M
+1.21%+2.18%-25.27%+2.96% 170B
+0.55%+2.47%-8.28%+17.81% 112B
+0.10%+0.69%-25.08%+3.95% 106B
+2.34%+1.21%-47.49%-10.79% 73.6B
+0.68%+5.22%+3.52%+74.65% 61.32B
+0.12%+2.73%+13.09%+67.70% 52.89B
+0.48%+3.85%-2.89%-30.92% 49.78B
+0.92%-0.43%-17.91%+16.71% 40.43B
-0.43%-1.56%+23.43%+1.13% 31.85B
Average +18.76%+1.16%-9.11%+4.79% 69.88B
Weighted average by Cap. +0.83%+1.54%-15.18%+13.54%

Financials

2023 2024
Net sales 530K 473K 440K 401K 756K 51.29M 759K 5.3M 2.08M 26.15M 1.99M 1.95M 83.92M 1.03M 924K 860K 782K 1.48M 100M 1.48M 10.35M 4.06M 51.07M 3.89M 3.8M 164M
Net income -55.36M -49.44M -45.99M -41.84M -78.99M -5.36B -79.33M -554M -217M -2.73B -208M -203M -8.77B -48.16M -43.02M -40.02M -36.4M -68.72M -4.66B -69.02M -482M -189M -2.38B -181M -177M -7.63B
Net Debt 21.78M 19.46M 18.1M 16.46M 31.08M 2.11B 31.22M 218M 85.35M 1.07B 81.8M 80.01M 3.45B 18.18M 16.24M 15.1M 13.74M 25.94M 1.76B 26.05M 182M 71.23M 897M 68.27M 66.78M 2.88B
Projected Income Statement - Annual - Orgenesis Inc.
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
26-10-06 US$0.3500 -36.36% 200
26-10-05 US$0.5500 -5.17% 100
26-10-02 US$0.5800 +5.45% 357
26-10-01 US$0.5500 -.--% 100
26-09-30 US$0.5500 -5.17% 100
  1. Stock Market
  2. Stocks
  3. ORGS Stock